So, secukinumab and ixekizumab are agents targeting IL17A, both approved for ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis (246); Bimekizumab that neutralizes both IL-17A and IL-17F is in preclinical phases for psoriatic arthritis and ankylosing spondylitis (247) and brodalumab an anti-IL17R, is approved for plaque psoriasis (248). Here, IL17F is linked to ankylosing spondylitis.